surmount-1 tirzepatide obesity nejm 2022 weight loss percent SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions GLP-1R Agonists for Weight Loss

Please note that order processing may take up to 2 weeks

These agents are integral in clinical practice to improve cardiovascular outcomes in patients with diabetes

Severe abdominal pain that spreads to the back, especially with vomiting, should be taken seriously

The peptide reconstitution calculator simplifies this planning

Further, data demonstrated that many participants reported the gastrointestinal side effects improved with slow titrating over time

From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently